PMID: 7030251Nov 1, 1981Paper

Serious infection in an adult due to penicillin-tolerant group B streptococcus

Archives of Internal Medicine
U P Steinbrecher

Abstract

This report describes a patient with group B streptococcal (GBS) bacteremia with pyelonephritis and septic arthritis whose condition failed to improve after two weeks of therapy with penicillin G sodium. The organism was found to be tolerant to penicillin (minimal inhibitory concentration, 0.06 IU/mL; minimal bactericidal concentration [MBC], 10 IU/mL). Antimicrobial synergy with gentamicin sulfate was demonstrated (MBC of penicillin was 0.07 IU/mL in the presence of 2.5 micrograms/mL of gentamicin). Addition of gentamicin to penicillin therapy was associated with clinical improvement. It is suggested that bactericidal rather than inhibitory susceptibility tests be employed as a guide to therapy in serious GBS infections. Where penicillin tolerance is found in association with a poor clinical response to penicillin, addition of an aminoglycoside should be considered. Antimicrobial synergy studies should be performed to demonstrate that a beneficial effect is possible at clinically attainable antibiotic concentrations.

Citations

Oct 1, 1986·Antimicrobial Agents and Chemotherapy·E TuomanenA Tomasz
Sep 1, 1982·Antimicrobial Agents and Chemotherapy·S M SmithS Landesman
Sep 1, 1994·Antimicrobial Agents and Chemotherapy·C BetriuJ J Picazo
Mar 1, 1993·Antimicrobial Agents and Chemotherapy·L L Silver, K A Bostian
Jan 1, 1996·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·Beatriz RosónFrancisco Gudiol

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.